business models

Pfizer and Big Data To Power Patient Care

An article written by Geno Germano, Group President, Global Innovative Pharma Business, Pfizer

How Pfizer Is Using Big Data To Power Patient Care, Forbes, 2/17/2015 @ 10:18AM
http://www.forbes.com/sites/matthewherper/2015/02/17/how-pfizer-is-using-big-data-to-power-patient-care/

February 24th, 2015|Big Data, Business|0 Comments|

On innovation, policies, economic returns – the cases of antibiotics , new and transformative drugs

In the current issue of Health Affairs :

February 2015; Volume 34, Issue 2 Biomedical Innovation
http://content.healthaffairs.org/content/34/2.toc

Outterson, K., J. H. Powers, G. W. Daniel and M. B. McClellan (2015). “Repairing The Broken Market For Antibiotic Innovation.” Health Affairs 34(2): 277-285. http://content.healthaffairs.org/content/34/2/277.abstract

“…Good public health practices curb inappropriate antibiotic use, making return on investment challenging in payment systems based on sales volume. We […]

3D bioprinting – printing cranial plugs, hearts, lungs, limbs … could we be printing drugs?

Maruthappu, M. and B. Keogh (2014). How might 3D printing affect clinical practice? BMJ 2014;349:g7709 http://www.bmj.com/content/349/bmj.g7709

Changing clinical practice and business models:

“When added to the ever increasing availability of printers,… The internet is no longer simply an information vehicle but a delivery vehicle, decentralising and accelerating the manufacturing process.”

“…combined with medical imaging, 3D printing also has the potential to revolutionise […]

Economic and scientific value creation – the case of stem cell medicine

Diverging standards still enable profit production and local forms of value creation.

Achim Rosemann, Standardization as situation-specific achievement: Regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine, Social Science & Medicine, Volume 122, December 2014, Pages 72-80,

http://www.sciencedirect.com/science/article/pii/S0277953614006649

January 13th, 2015|Regulation, Research, Value|0 Comments|

McKinsey report: A digital prescription for pharma companies

Patients are changing, Governments are moving… “Pharmaceutical and medical-device companies have been slow to adopt digitization. Here are five reasons they should get moving…”

for digitally enabled healthcare…

 

The report is here: http://www.mckinsey.com/insights/health_systems_and_services/a_digital_prescription_for_pharma_companies

 

December 6th, 2014|Business, Medicine|0 Comments|

On value and the new pharmaceutical “commons”

The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development
by Javier Lezaun and Catherine M. Montgomery

Science, Technology & Human Values January 2015 40: 3-29,
first published on July 11, 2014
doi:10.1177/0162243914542349

In the last decade, the organization of pharmaceutical research on neglected tropical diseases has undergone transformative change. In a context of perceived “market failure,” the development of […]

July 14th, 2014|Value|0 Comments|

Social networks ‘big data’ + drug manufacturing

PatientsLikeMe, the largest online network for patients, has established its first broad partnership with a drug company. Genentech
http://www.technologyreview.com/

Ten digital pharma failures

A blog post by Dom Marchant & Matt Lowe, on how “digital is no longer a bolt-on, but the predominant channel within pharma”, and ten things not to do in the business..

Read more at: http://www.pharmatimes.com/magazine/blogdetails.aspx?id=0ebffbc3-bed0-4c9b-b260-642dfec06c85#.Uwtko8umGU8.email#ixzz3L8Czz4sC

February 24th, 2014|Business|0 Comments|

Creating a new ecosystem for drug discovery

An article from Pharma Times, by Claire Bowie, on intellectual property and Pharma-University collaboration

Creating a new ecosystem for drug discovery
Pharma Times FEBRUARY 24, 2014

February 24th, 2014|Research|0 Comments|